Tiffany Redfern, MD, FACOG

Tiffany Redfern, MD, FACOG, is a gynecologic oncologist at Texas Oncology in Austin.

Articles

Ongoing Research to Watch in Ovarian Cancer in 2025

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss ongoing research and areas of potential investigation in ovarian cancer.

Highlighting Key Ovarian Cancer Data from the 2025 SGO Annual Meeting

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss updates in ovarian cancer from the 2025 SGO Annual Meeting.

Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.

PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer

April 3rd 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on final overall survival data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Current Treatment Approaches and Challenges in Platinum-Resistant Ovarian Cancer

March 31st 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss current treatment approached in platinum-resistant ovarian cancer.

x